The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases
Authors Bayiz H, Ozkaya, Dirican A, Ece F
Received 15 June 2015
Accepted for publication 4 August 2015
Published 21 September 2015 Volume 2015:9 Pages 5287—5290
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Chao Tai
Peer reviewer comments 3
Editor who approved publication: Professor Shu-Feng Zhou
Hulya Bayiz,1 Sevket Ozkaya,1 Adem Dirican,2 Ferah Ece1
1Department of Pulmonary Medicine, Faculty of Medicine, Bahcesehir University, Istanbul, 2Department of Pulmonary Medicine, Samsun Medical Park Hospital, Samsun, Turkey
Introduction: The use of a combination inhaler containing budesonide and formoterol (BUD/FOR) to both maintenance and quick relief therapy has been recommended as an improved method of using inhaled corticosteroid/long-acting β agonist therapy. The aim of this study was to investigate the acute effects of BUD/FOR and testing the availability of BUD/FOR for early reversibility test in patients with airway obstruction.
Patients and methods: The study was conducted on patients who were admitted to the Department of Pulmonary Medicine, Samsun Medical Park Hospital, Samsun, Turkey.
Results: A total of 44 patients were included in the study. The mean age of patients was 48.5±17.3 (range 10–75) years and the male-to-female ratio was 36:8. The pre-bronchodilator pulmonary function test results are as follows: the mean forced vital capacity, 3,025±1,162 mL (76.3%±23.2%); mean forced expiratory volume in 1 second (FEV1), 1,898±725 mL (59.2%±19.1%); mean FEV1/forced vital capacity, 62.8±6.3% (range 42%–70%); mean peak expiratory flow, 3,859±1,779 mL (48.0%±19.7%); and forced expiratory flow 25%–75%, 1,295±486 mL (35.8%±12.3%). The reversibility was positive in 26 (59.1%) patients. The absolute change and percentage of change in FEV1 were 318±228 mL and 17.7%±11.9%, respectively. The patients were divided into two groups according to reversibility (reversible and irreversible) and both groups were compared with changes according to spirometric results. FEV1 values were statistically different between the two groups.
Conclusion: The fixed combination of BUD/FOR has rapid bronchodilator effect, and they can be used for early reversibility test.
Keywords: formoterol/budesonide, reversibility test, asthma, chronic obstructive pulmonary disease
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]